Labaton Sucharow Files Antitrust Class Action Against Johnson & Johnson Regarding Biologic Medication

NEW YORK (October 27, 2017) – Labaton Sucharow LLP filed today a class action complaint on behalf of UFCW Local 1500 Welfare Fund against Johnson & Johnson and Janssen Biotech, Inc. (collectively, J&J) for claims under federal and state antitrust laws and state consumer protection laws.

The plaintiff seeks to recover damages and obtain injunctive and equitable relief for the substantial injuries it and others similarly situated have sustained arising from J&J’s anticompetitive scheme to abuse its monopoly power, exclude competition, and raise prices for Remicade®, a biologic medication used to treat chronic illnesses such as rheumatoid arthritis, plaque psoriasis, and Crohn’s disease.

For more details on the allegations, the complaint can be viewed here.